Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Zenz

Showing results (81-90 of 183) with videos related to

Pageof 19
Sort By:
Haematologica|August 18, 2010
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical riskDirk Winkler, Christof Schneider, Manuela Zucknick, et al.
British Journal of Haematology|May 23, 2024
B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphomaKevin D Hofer, Nathan Wolfensberger, Adrian Bachofner, et al.
Journal for Immunotherapy of Cancer|May 1, 2021
Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axisMartin Böttcher, Heiko Bruns, Simon Völkl, et al.
Blood Cancer Journal|January 21, 2018
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemiaPatricia Johansson, Ludger Klein-Hitpass, Axel Choidas, et al.
Hemasphere|June 24, 2022
CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNSWiebke Rösler, Andrea Bink, Marina Bissig, et al.
Leukemia|May 16, 2019
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemiaStephan Stilgenbauer, Thérèse Aurran Schleinitz, Barbara Eichhorst, et al.
Leukemia|May 15, 2020
Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependenciesMarina Lukas, Britta Velten, Leopold Sellner, et al.
Blood|November 19, 2020
IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigeneticsFerran Nadeu, Romina Royo, Guillem Clot, et al.
Blood Advances|June 23, 2023
Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignanciesSophie A Herbst, Vladislav Kim, Tobias Roider, et al.
Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Pageof 19

Showing results (81-90 of 183) with videos related to

Sort By:
Pageof 19
Haematologica|August 18, 2010
Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical riskDirk Winkler, Christof Schneider, Manuela Zucknick, et al.
British Journal of Haematology|May 23, 2024
B-cell maturation antigen-directed bispecific antibodies in plasmablastic lymphomaKevin D Hofer, Nathan Wolfensberger, Adrian Bachofner, et al.
Journal for Immunotherapy of Cancer|May 1, 2021
Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axisMartin Böttcher, Heiko Bruns, Simon Völkl, et al.
Blood Cancer Journal|January 21, 2018
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemiaPatricia Johansson, Ludger Klein-Hitpass, Axel Choidas, et al.
Hemasphere|June 24, 2022
CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNSWiebke Rösler, Andrea Bink, Marina Bissig, et al.
Leukemia|May 16, 2019
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemiaStephan Stilgenbauer, Thérèse Aurran Schleinitz, Barbara Eichhorst, et al.
Leukemia|May 15, 2020
Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependenciesMarina Lukas, Britta Velten, Leopold Sellner, et al.
Blood|November 19, 2020
IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigeneticsFerran Nadeu, Romina Royo, Guillem Clot, et al.
Blood Advances|June 23, 2023
Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignanciesSophie A Herbst, Vladislav Kim, Tobias Roider, et al.
Blood|July 4, 2013
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGAndrea Schnaiter, Peter Paschka, Marianna Rossi, et al.
Pageof 19